Analisis Potensi Interaksi Obat Antipsikotik Pada Pasien Skizofrenia
Abstract
Background: Schizophrenia is a complex psychiatric disorder, characterized by disturbances in the form of delusions, hallucinations, disorganized thoughts and changes in behavior. One of the treatment for schizophrenia is using antipsychotic combination therapy. This can lead to drug interactions
Objective: This study aims to see the description and potential interactions of antipsychotic drugs with lexicomp.
Method: Descriptive research using retrospective method. Drug interaction data were taken from 160 medical records of schizophrenic patients inpatients at Ernaldi Bahar Hospital Palembang in 2020
Result: According to research and calculations, public service motivation influences Based on the characteristics of patients, the highest age of schizophrenic patients was at the age of 18-30 (41.25%), the most severe schizophrenic patients suffered (76.87%), then the highest education level of schizophrenic patients was Elementary School (37.5%), diagnosed with schizophrenia patients who suffered the most from paranoid schizophrenia (78.74%). The most commonly prescribed single antipsychotic drug was risperidone (35.63%). The use of antipsychotic drugs combined with two types of drugs chlorpromazine-risperidone as many as 16 patients (10%). The most use of antipsychotic drugs in combination with three types of drugs, namely haloperidol-clozapine-quetiapine in 2 patients (1.25%) and clozapine-risperidone-haloperidol in 2 patients (1.25%). The potential for pharmacodynamic drug interactions of antipsychotic drugs is more (78.43%) than pharmacokinetics (21.35%). Potential drug interactions based on severity are major (52.94%), moderate (25.49%), minor (21.57%) and drug interactions that occur in schizophrenic patients hospitalized at Ernaldi Bahar Hospital are 9 patients (8, 82%)
Full Text:
PDFReferences
. Wells BG, Dipiro JT, Dipiro CV, Schwinghammer TL. Pharmacotherapy Handbook. Vol. 7. 2009. 31–42 p.
. Organization WH. Improving health systems and services for mental health. World Health. 2009;112. Available from: http://apps.who.int/iris/bitstream/handle/10665/44219/9789241598774_eng.pdf?sequence=1%0Ahttp://www.who.int/mental_health/policy/services/mhsystems/en/index.html
. Kementerian Kesehatan Republik Indonesia. HASIL UTAMA RISKESDAS 2018 Kesehatan [Main Result of Basic Heatlh Research]. Riskesdas. 2018;52. Available from: http://www.depkes.go.id/resources/download/info-terkini/materi_rakorpop_2018/Hasil Riskesdas 2018.pdf
. American Psychiatric Association. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. 2020. https://doi.org/10.1176/appi.books.9780890424841
. St?pnicki P, Kondej M, Kaczor AA. Current concepts and treatments of schizophrenia. Molecules. 2018;23(8). https://doi.org/10.3390/molecules23082087
. Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizoaffective disorder: Findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry. 2008;165(11):1420–31. https://doi.org/10.1176/appi.ajp.2008.08050756
. Girgis RR, Javitch JA, Lieberman JA. Antipsychotic drug mechanisms: Links between therapeutic effects, metabolic side effects and the insulin signaling pathway. Mol Psychiatry. 2008;13(10):918–29. https://doi.org/10.1038/mp.2008.40
. Wijesinghe R. A review of pharmacokinetic and pharmacodynamic interactions with antipsychotics. Ment Heal Clin. 2016;6(1):21–7. https://doi.org/10.9740/mhc.2016.01.021
. English BA, Dortch M, Ereshefsky L, Jhee S. Clinically significant psychotropic drug-drug interactions in the primary care setting. Curr Psychiatry Rep. 2012;14(4):376–90. https://doi.org/10.1007/s11920-012-0284-9
. Ramdini DA, Sumiwi SA, Barliana MI, Destiani DP, Nur IL. Potensi Interaksi Obat pada Pasien Skizofrenia di Salah Satu Rumah Sakit Jiwa di Provinsi Jawa Barat. Indones J Clin Pharm. 2018;7(4):280. https://doi.org/10.15416/ijcp.2018.7.4.280
. Aburamadan H, Sridhar S, Tadross T. Assessment of potential drug interactions among psychiatric inpatients receiving antipsychotic therapy of a secondary care hospital, United Arab Emirates. J Adv Pharm Technol Res. 2021;12(1):45–51. https://doi.org/10.4103/japtr.JAPTR_110_20
. Zahnia S, Wulan Sumekar D. Kajian Epidemiologis Skizofrenia. Majority. 2016;5(5):160–6. Available from: http://juke.kedokteran.unila.ac.id/index.php/majority/article/view/904/812
. Jiwa BK, Keperawatan F, Syiah U, Banda K. Karakteristik Pasien Skizofrenia Dengan Riwayat Rehospitalisasi. Idea Nurs J. 2016;7(3):23–9.
. Sun J, Zhao M, Fanous AH, Zhao Z. Characterization of schizophrenia adverse drug interactions through a network approach and drug classification. Biomed Res Int. 2013;2013. https://doi.org/10.1155/2013/458989
. Yulianty MD, Cahaya N, Srikartika VM. Antipsychotics use and side effects in patients with schizophrenia at Sambang Lihum Hospital South Kalimantan, Indonesia. J Sains Farm Klin. 2017;3(2):153–64. Available from: http://jsfkonline.org/index.php/jsfk/article/view/108
. Buselli R, Corsi M, Baldanzi S, Chiumiento M, Lupo E Del, Dell’oste V, et al. Professional quality of life and mental health outcomes among health care workers exposed to SARS-CoV-2 (COVID-19). Int J Environ Res Public Health. 2020;17(17):1–12. https://doi.org/10.3390/ijerph17176180
. Gonzalez-Zacarias AA, Mavarez-Martinez A, Arias-Morales CE, Stoicea N, Rogers B. Impact of Demographic, Socioeconomic, and Psychological Factors on Glycemic Self-Management in Adults with Type 2 Diabetes Mellitus. Front Public Heal. 2016;4(September):1–8. https://doi.org/10.3389/fpubh.2016.00195
. Herz MI, Liberman RP, McGlashan TH, Lieberman JA, Wyatt RJ, Marder SR, et al. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 1997;154(4 SUPPL.):1–63. https://doi.org/10.1176/ajp.154.4.1
. Castle DJ, Galletly CA, Dark F, Humberstone V, Morgan VA, Killackey E, et al. The 2016 royal australian and New Zealand college of psychiatrists guidelines for the management of schizophrenia and related disorders. Med J Aust. 2017;206(11):501–5. https://doi.org/10.5694/mja16.01159
. S CO, Le C, Hu Y, Maayan N, Ce A, S CO, et al. Ortiz-Orendain J, Castiello-de Obeso S, Colunga-Lozano LE, Hu Y, Maayan N, Adams CE. Antipsychotic combinations for schizophrenia. Cochrane Database of Systematic Reviews 2017, Issue 6. Art. No.: CD009005. 2017; https://doi.org/10.1002/14651858.CD009005.pub2.www.cochranelibrary.com
. Siafis S, Tzachanis D, Samara M, Papazisis G. Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects. Curr Neuropharmacol. 2017;16(8):1210–23. https://doi.org/10.2174/1570159x15666170630163616
. Tiihonen J, Taipale H, Mehtälä J, Vattulainen P, Correll CU, Tanskanen A. Association of Antipsychotic Polypharmacy vs Monotherapy with Psychiatric Rehospitalization among Adults with Schizophrenia. JAMA Psychiatry. 2019;76(5):499–507. https://doi.org/10.1001/jamapsychiatry.2018.4320
. Furukawa TA, Levine SZ, Tanaka S, Goldberg Y, Samara M, Davis JM, et al. Initial severity of schizophrenia and efficacy of antipsychotics: Participant-level meta-analysis of 6 placebo-controlled studies. JAMA Psychiatry. 2015;72(1):14–21. https://doi.org/10.1001/jamapsychiatry.2014.2127
. Gareri P, De Fazio P, De Fazio S, Marigliano N, Ibbadu GF, De Sarro G. Adverse effects of atypical antipsychotics in the elderly: A review. Drugs and Aging. 2006;23(12):937–56. https://doi.org/10.2165/00002512-200623120-00002
. Ocaña-Zurita MC, Juárez-Rojop IE, Genis A, Tovilla-Zárate CA, González-Castro TB, Lilia López-Narváez M, et al. Potential drug–drug interaction in Mexican patients with schizophrenia. Int J Psychiatry Clin Pract. 2016;20(4):249–53. https://doi.org/10.1080/13651501.2016.1213854
. Siwek M, Woro? J, Gorostowicz A, Wordliczek J. Adverse effects of interactions between antipsychotics and medications used in the treatment of cardiovascular disorders. Pharmacol Reports. 2020;72(2):350–9. https://doi.org/10.1007/s43440-020-00058-6
. Puspitasari AW, Angeline L. Analisis Potensi Interaksi Obat Golongan Antidepresan pada Pasien Skizofrenia di Rumah Sakit Jiwa Dr. Soeharto Heerdjan Tahun 2016. Pharm Sci Res. 2019;6(1):13–20. https://doi.org/10.7454/psr.v6i1.4196
. Sakit R, Prof J. Potensi Interaksi Obat Antipsikotik Pada Pasien Skizofrenia. 2021;4(1):88–96.
DOI: https://doi.org/10.35730/jk.v14i0.1084
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.